Targets › ADAMTS13
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Neurology, Immunology; next expected readout Mar 2027.
Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation. (UniProt, Q76LX8)
Open in Phaseline: the race on ADAMTS13, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Apadamtase Alfa (TAK-755) A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein | ADAMTS13 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP); Acute Ischemic Stroke | Mar 2027 |
Thrombotic Thrombocytopenic Purpura (TTP) (1) Acute Ischemic Stroke (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.